lowering drug Vytorin did not lower the risk of heart-valve problems or the need for surgery. Its shares fell 6 percent.
The broader Standard & Poor's 500 index was little changed, falling 0.68 to 1,260.00. The technology-heavy Nasdaq composite (...)
